Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.

Riziero Esposito AbateRaffaella PasqualeAlessandra SaccoVittorio SimeonMonica Rosaria MaielloDaniela FrezzettiPaolo ChiodiniNicola Normanno

Published in: Journal for immunotherapy of cancer (2024)

This study estimated TMB cut-off values for commercially available CGP panels. The results showed a good performance of all panels on clinical samples and the calculated cut-offs support better accuracy measures for TSO500. The validated cut-off values can drive clinical interpretation of TMB testing in clinical research and clinical practice.

Keyphrases

clinical practice
high throughput
gene expression
single cell
risk factors